相关实验视频
Updated: Sep 10, 2025

Production and Detection of Reactive Oxygen Species ROS in Cancers
Published on: November 21, 2011
癌症中的氧化应激:从瘤和微环境重塑到治疗边界
Xisong Liang1,2,3, Jiadi Weng1,2,3,4, Zhongyi You1,2,3,4
1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
氧化压力是反应性氧物种 (ROS) 的失衡, 是癌症的关键. 针对这一网络提供了新的治疗策略, 特别是与免疫疗法和纳米医学相结合,
科学领域:
- 癌症学
- 细胞生物学
- 癌症治疗方法
背景情况:
- 氧化应激是由高活性氧物种 (ROS) 引起的氧化回归信号失调和宏分子损伤的特征,是癌症的关键标志.
- 它显著影响瘤细胞生长和瘤微环境,使其成为癌症治疗开发的关键目标.
- 针对氧化应激的挑战源于它在不同癌症中的复杂和异质调节.
研究的目的:
- 全面了解瘤细胞中的氧化应激网络及其在癌症中的作用.
- 审查目前针对癌症氧化应激的治疗策略.
- 突出新兴的临床应用和基于氧化应激的方法的潜力,特别是在组合疗法中.
主要方法:
- 对癌症中氧化应激产生和调节的现有文献的审查.
- 对瘤细胞和瘤微环境中的氧化应激作用的分析.
- 目前和新兴治疗策略的总结,包括与免疫疗法和纳米医学的结合.
主要成果:
- 氧化应激网络是癌症生物学不可或缺的一部分,影响瘤细胞及其微观环境.
- 目前针对氧化应激的治疗策略具有前景,但由于癌症异质性而面临挑战.
- 氧化应激向疗法与免疫疗法和纳米医学的结合提供了协同效应的优势.
结论:
- 氧化压力是癌症治疗的关键目标,对癌症生物学有重大影响.
- 将氧化应激向方法与免疫疗法和纳米医学结合在一起, 是改善癌症治疗的有希望途径.
- 未来的研究应该集中在克服治疗耐药性和开发结合疗法平台以实现癌症消除.
更多相关视频
09:31Analyzing Oxidative Stress in Murine Intestinal Organoids using Reactive Oxygen Species-Sensitive Fluorogenic Probe
Published on: September 17, 2021
10:23Author Spotlight: Computing the Effects of a Local Radiofrequency Hyperthermia Intervention on Tumor Biomechanics
Published on: December 1, 2023
相关概念视频
The Tumor Microenvironment
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers